Embed Size (px)
Citation preview
F A C T S &
FIGURES
P R O F I L E2 0 1 9
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
2 03
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
CREATING A FUTURE WORTH LIVING.
FOR PATIENTS.
WORLDWIDE. EVERY DAY.
O U R P U R P O S E
Fresenius Medical Care is the world’s leading provider of dialysis products and services. We care for people with chronic kidney failure, of whom around 3.5 million worldwide depend on dialy-sis treatment. Thanks to our decades of experience in dialysis, our innovative research and our value-based care approach, we can help them to enjoy the very best quality of life.
WH
OW
E A
RE
WH
ATW
E D
O
We care for over 345,000 dialysis patients. Their well-being always comes first. Our top priority is to offer them the best possible treatment. To this end, our portfolio encompasses a comprehensive range of high-quality health care products and services as well as various dialysis treatment options for both in-center and home dialysis that are individually tailored to our patients’ needs.
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
04 05
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
1996W I T H C O R P O R AT E H E A D Q U A R T E R S
I N B A D H O M B U R G , G E R M A N Y
S I N C E
I N H E A LT H C A R E S O L U T I O N S
F O R PAT I E N T S W I T H C H R O N I C
K I D N E Y FA I L U R E
AT AGLANCE
€ 17.48B N
R E V E N U E
P R O D U C T I O N S I T E S45
There are regions in the world where people with chronic kidney
disease still do not have direct access to dialysis. We aim to change this.”
R I C E P O W E L L
CEO and Chairman of the Management
Board
E M P L O Y E E S120,659
P R O D U C T S A N D T R E AT M E N T S I N
A R O U N D
C O U N T R I E S
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
06 07
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LEThere are three
options for treating chronic kidney failure: hemodialysis, peritoneal dialysis or transplantation.
V A R I O U S F O R M S
O F I N F E C T I O N
B L O O D P R E S S U R E
HIGH
CA
US
ES
M I L L I O N P E O P L E W O R L D W I D E
D E P E N D O N D I A LY S I S T R E AT M E N T.
3.5A R O U N D
12%H O M E D I A LY S I S
CHRONIC KIDNEY FAILUREPeople with kidney failure are not able to remove excess water and toxins from the body through their kidneys and urine.
Peritoneal dialysis is typically administered several times a day by patients themselves at home or at work and using a machine, a so-called cycler, at night.
PERITONEAL DIALYSIS
The process of filtering blood and removing waste products and excess fluid from the body.
DIALYSIS
Hemodialysis is the most common procedure in renal replacement therapy. It usually takes three to six hours and is performed at least three times a week, usually in a dialysis center – but there are options for home hemodialysis.
HEMODIALYSIS
88%I N - C E N T E R D I A LY S I S
D I A LY S I S PAT I E N T S :
DIABETES
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
08 09
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
52M I L L I O N D I A LY S I S
T R E AT M E N T S I N 2 0 1 9
A R O U N D HEALTH CARE SERVICES
End-Stage Renal Disease-related treatments
End-Stage Renal Disease-related laboratory testing services
Acute dialysis services Pharmacy services Vascular, cardiovascular and endovascular specialty services
Ambulatory surgery center services Value and risk based arrangements Urgent care services Physician nephrology services Ambulant treatment services
A R O U N D
M I L L I O N D I A LY Z E R S P R O D U C E D
I N 2 0 1 9
0.6 sW E P R O V I D E A D I A LY S I S T R E AT M E N T
E V E R Y
OURPORTFOLIO
HEALTH CARE PRODUCTS
Hemodialysis machines Peritoneal dialysis cyclers Dialyzers Peritoneal dialysis solutions Hemodialysis concentrates, solutions and granulates
Bloodlines Systems for water treatment Renal pharmaceuticals Other equipment and medical devices Acute cardiopulmonary products Apheresis products
167 D I A LY S I S M A C H I N E S
W O R L D W I D E I S M A D E B Y F R E S E N I U S M E D I C A L
C A R E
O F
1
2
D I A LY S I S C E N T E R S I N A R O U N D 5 0 C O U N T R I E S
3,994
PAT I E N T S
345,096
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
10 11
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LEREVENUE
2 0 1 9
thereof HEALTH CARE
SERVICES
thereof HEALTH CARE
PRODUCTS
70 %NORTH AMERICA
4 %LATIN
AMERICA
15 %EUROPE,
MIDDLE EAST AND AFRICA
11 % ASIA-PACIFIC
4 %LATIN
AMERICA
6 %LATIN
AMERICA
80 %NORTH AMERICA
29 %NORTH AMERICA 10 %
EUROPE, MIDDLE
EAST AND AFRICA
37 %EUROPE,
MIDDLE EAST AND AFRICA
6 % ASIA-PACIFIC
28 % ASIA-
PACIFIC
€ 3.61B N
€ 13.87B N
€ 17.48BN
SELECTED KEY FIGURES in € M, except where otherwise specified
2019 2018 Change
Operating income 2,270 3,038 –28 % cc
Operating income adjusted 3 2,296 2,292 –4 % cc
Basic earnings per share in € 3.96 6.47 –41 % cc
Basic earnings per share adjusted 3 in € 4.52 4.37 –1 % cc
Net cash provided by (used in) operating activities 2,567 2,062 24 %
Free cash flow 4 1,454 1,059 37 %
Capital expenditures, net (1,113) (1,003) 11 %
Aquisitions and investments (excluding investments in debt securities), net (2,178) 1,088
Operating income margin adjusted 3 in % 13.2 14.3
Return on invested capital (ROIC) 5, 6 in % 6.8 12.4
Net leverage ratio 5, 6 2.5 1.8
Equity ratio (equity/total assets) 6, 7 in % 47.0 49.2
cc = constant currency1 2019 adjusted for the effect of the IFRS 16 implementation and the contribution of NxStage; 2018 adjusted for the contribution of Sound
Physicians in H1 2018.2 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.3 2019 adjusted for the effect of the IFRS 16 implementation, the effects of the NxStage acquisition, expenses for the cost optimization program
and the gain related to divestitures of Care Coordination activities; 2018 adjusted for the contribution of Sound Physicians in H1 2018, the gain related to divestitures of Care Coordination activities and the FCPA related charge.
4 Net cash provided by (used in) operating activities after capital expenditures, before acquisitions and investments.5 See calculation in form 20-F 2019, operating and financial review and prospects, performance management system.6 Adjusted for the effect of the IFRS 16 implementation.7 As of December 31 of the respective year.
NET INCOME ²IN € M
REVENUEIN € M
CHANGE
+2 % CONSTANT CURRENCY
CHANGE
– 42 % CONSTANT CURRENCY
REVENUE ADJUSTED 1
IN € M
NET INCOME ²ADJUSTED 3
IN € M
CHANGE
+ 5 % CONSTANT CURRENCY
CHANGE
– 2 % CONSTANT CURRENCY
16,5472 0 1 8
17,4772 0 1 9
1,9822 0 1 8
1,2002 0 1 9
16,0262 0 1 8
17,3292 0 1 9
1,3692 0 1 9
1,3412 0 1 8
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
12 13
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LEEUROPE,
MIDDLE EASTAND AFRICA
2 0 1 9
NORTH AMERICA
2 0 1 9
Revenue € 12.2 BN
– Health care services € 11.2 BN
– Health care products € 1.0 BN
Employees 1 60,478
Patients 211,064
Treatments 32 M
Clinics 2,579
LATIN AMERICA
2 0 1 9
Revenue € 0.7 BN
– Health care services € 0.5 BN
– Health care products € 0.2 BN
Employees 1 10,469
Patients 34,810
Treatments 5 M
Clinics 234
ASIAPACIFIC 2 0 1 9
Revenue € 1.9 BN
– Health care services € 0.9 BN
– Health care products € 1.0 BN
Employees 1 11,836
Patients 33,005
Treatments 5 M
Clinics 400
1 Full-time equivalents.2 Inclusive Mexico.
Revenue € 2.7 BN
– Health care services € 1.4 BN
– Health care products € 1.4 BN
Employees 1 20,103
Patients 66,217
Treatments 10 M
Clinics 781
BAD HOMBURG
D EWALTHAM
U . S .
RIO DE JANEIROB R
HONG KONGC N
OURREGIONS
+ 3 – 4%+ 7 – 9%
+ 3 – 4%
+ 3 – 4%2
Average annual growth rate of dialysis patients (2019 – 2025) based on Company data and estimates.
Company headquarters and regional headquarters.
Regional headquarters.
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
14 15
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
BASIC SHARE DATA
Ticker symbols
Frankfurt Stock Exchange / Prime Standard FME
New York Stock Exchange (NYSE) FMS
Reuters: XETRA / ADR NYSE FMEG.DE / FMS.N
Bloomberg: XETRA / ADR NYSE FME GY / FMS US
Security identification codes
WKN 578580
ISIN DE0005785802
CUSIP No. (NYSE) 358029106
SHARE PRICE PERFORMANCE – 2019
DIVIDEND PER SHARE IN €
6M AY
19M AY
FINANCIAL CALENDAR
2020
25M AY
30J U LY
Payment of dividend Subject to the approval by the
Annual General Meeting
Report on second quarter 2020
Report on first quarter 2020
Annual General Meeting, Frankfurt am Main
(Germany)
IMPRINTPUBLISHED BY
Fresenius Medical Care AG & Co. KGaA
EDITORIAL OFFICE
Corporate Communications
CONCEPT AND DESIGN
MPM Corporate Communication Solutions, Mainz, Düsseldorf www.mpm.de
PICTURE CREDITS
Matthias Haslauer: Cover, Katrin Binner: p. 5, Ken Richardson: p. 6 – 7
Fresenius Medical Care: p. 8 – 9
29O C T O B E R
Report on third quarter 2020
Subject to change.
IN €
40
50
60
70
80
90
J A N F E B M A R A P R M AY J U N E J U LY A U G S E P T O C T N O V D E C
carbon neutralnatureOffice.com | DE-140-1VLKBCE
print production
1.172 0 1 8
1 Proposal to be approved by the Annual General Meeting on May 19, 2020.
1.20 ¹
2 0 1 9CHANGE
+ 3 %
FR
ES
EN
IUS
ME
DIC
AL
CA
RE
20
19
PR
OFI
LE
16
FRESENIUS MEDICAL CARE
Else -Kroener-Str. 1
61352 Bad Homburg v. d. H.
Germany
www.freseniusmedicalcare.com
fmc_ag
freseniusmedicalcare.corporate
freseniusmedicalcare
